Indeed, the FDA recently approved the TLR2/TLR4 agonist Bacillus Calmette-Guérin (BCG), the TLR2/TLR4 agonist monophosphoryl lipid A (MPL) and the TLR9 agonist imiquimod as anti-tumor agents [3]. The gene discussed is TLR9; the disease is neoplasm.